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ABSTRACT: One of the main hurdles in nanomedicine is the
low stability of drug−nanocarrier complexes as well as the
drug delivery eﬃciency in the region-of-interest. Here, we
describe the use of the ﬁlm-forming protein hydrophobin
HFBII to organize dodecanethiol-protected gold nanoparticles
(NPs) into well-deﬁned supraparticles (SPs). The obtained
SPs are exceptionally stable in vivo and eﬃciently encapsulate
hydrophobic drug molecules. The HFBII ﬁlm prevents
massive release of the encapsulated drug, which, instead, is
activated by selective SP disassembly triggered intracellularly
by glutathione reduction of the protein ﬁlm. As a consequence, the therapeutic eﬃciency of an encapsulated anticancer
drug is highly enhanced (2 orders of magnitude decrease in IC50). Biodistribution and pharmacokinetics studies
demonstrate the high stability of the loaded SPs in the bloodstream and the selective release of the payloads once taken up
in the tissues. Overall, our results provide a rationale for the development of bioreducible and multifunctional
nanomedicines.
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In the last decades the use of nanosized objects has beenextensively exploited for improving in vivo drug delivery.1In fact, encapsulation of hydrophobic drugs into nano-
carriers has been proven to increase their stability and
circulating time in the blood as well as reduce their unspeciﬁc
toxicity and cell resistance.2 Toward reaching these goals, a
myriad of nanotechnology-based drug delivery systems has
been deployed, comprising, among others, liposomes, core−
shell nanoparticles (NPs) of diﬀerent nature, and nano-
tubes.1,3,4 However, nanocarrier-based delivery has not yet
reached the hoped results in clinics.5 One of the main hurdles is
the low stability of drug−nanocarrier complexes in the
biological environment, which often results in an undesired
drug leakage in the biological ﬂuids, in particular in the
bloodstream for intravenously injected formulations. This often
leads to two main side-eﬀects: on one side, the penetration of
drugs in the brain, heart, or other vital organs, and, on the other
side, the rapid drug clearance from the kidneys. In this context,
the role of ﬁlter organs is extremely important, such as the liver
and the spleen, crucial to avoid systemic toxicity through an
eﬃcient interaction of resident immunocompetent cells.6
NPs can spontaneously assemble in solution into well-
deﬁned larger structures called supraparticles (SPs), which may
serve as containers for the transport and controlled release of
therapeutic agents.7−9 SPs have recently gained particular
interest for their use in medicine, for example, to evaluate the
onset, progression, and treatment of various pathologies by
enhancing both imaging and therapeutic performances of
drugs.10−14 In order to assemble NPs into SPs, various surface
chemistries have been exploited using surfactants, lipids,
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polymers, or proteins, which drive the self-assembly in solution
as a result of a subtle balance of noncovalent interactions, such
as hydrogen bonding, Coulombic and van der Waals (vdW)
interactions, and solvophobic eﬀect.9,15,16 However, program-
ming hierarchical structure into nanoscale components remains
a formidable challenge for nanoscientists.
Several SPs reported in the literature were obtained through
controlled aggregation of water-soluble NPs with biomole-
cules.7,14,17 Formation of hybrid SPs composed of hydrophobic
NPs in aqueous solutions has also been obtained, exploiting the
amphiphilic nature of lipids,18−20 surfactants,21,22 and poly-
mers.10,23,24 In this latter case, the assembly is driven by the
hydrophobic eﬀect with formation of deﬁned SPs constituted of
a core of assembled hydrophobic NPs coated by an amphiphilic
molecule. While lipid vesicles containing NP clusters generally
need puriﬁcation procedures for obtaining homogeneous
samples, polymers and surfactants give uniform SPs through
simple methodologies (high yield and low cost),10,25,26 but
often the constituents are poorly metabolized and promote
immunological responses.27 A promising alternative for
obtaining biocompatible SPs through simple preparation
methods is represented by the use of Janus proteins, that is,
biomolecules endowed with a conﬁned highly hydrophobic
patch. These biosurfactants may act as template agents that
spontaneously assemble hydrophobic NPs in aqueous solutions
forming well-deﬁned SPs, which result to be biocompatible and
partially biodegradable.14
Hydrophobins are small fungal amphiphilic proteins with
remarkable surface activity.28 Hydrophobin HFBII, obtained
from Trichoderma reesei, forms rigid and impermeable ﬁlms at
interfaces preventing the leakage of volatile oils into water, even
at high temperature.29 It has also been shown that HFBII ﬁlms
prevent immune recognition.30−32 Considering that HFBII may
form a solid robust ﬁlm on hydrophobic NPs dispersed in water
solution, we studied the self-assembly of dodecanethiol (DT)-
stabilized AuNPs into aqueous solutions in the presence of
HFBII. A class of SPs that showed low cytotoxicity and
exceptional stability, even in biological ﬂuids, has been
synthesized and characterized. The obtained SPs not only
eﬃciently encapsulated and protected hydrophobic drug
molecules by means of the HFBII ﬁlm but also speciﬁcally
released their payload intracellularly by glutathione reduction of
Figure 1. SP structure and starting building blocks. (a) DT-AuNPs used as building blocks for SP self-assembly: yellow represents the AuNP
and blue the dodecanethiol stabilizing shell. (b) Cartoon sketching HFBII molecular structure derived from the PDB ﬁle 2B97 (left) and its
relative schematic representation (right). Color code of the protein secondary structure: red (β sheet) and green ribbon (α helix), while the
amino acids of the hydrophobic patch are depicted in blue. (c) Self-assembly of DT-AuNPs into a SP is driven by the formation of a HFBII
ﬁlm at the interface where the HFBII hydrophobin patch interacts with the DT ligands on the AuNP surface.
Figure 2. Physical-chemical properties of the self-assembled SPs. (a) Representative TEM image of DT-AuNPs and corresponding size
distribution obtained by the analysis of around 100 NPs. (b) Representative TEM image of a dried water dispersion of SPs with the
corresponding size distribution obtained by the analysis of around 100 SPs. The inset reports a TEM magniﬁcation of one SP. (c) Normalized
UV−vis spectrum of chloroform dispersed DT-AuNPs (black line) and water dispersed SPs (red line). (d) Normalized DLS intensity-weighed
size distribution of chloroform dispersed DT-AuNPs (NP, black line) and water dispersed SPs (SP, red line). (e) Normalized DLS
autocorrelation function curves of water dispersed SPs measured over a time course of two months from their preparation. The plot highlights
the kinetic stability of the SP dispersion. (f) Evaluation of the SP physicochemical stability over a pH scan: Dependence of the Z-pot (top of
the plot) and the SP size (bottom of the plot) as a function of the pH of the buﬀer used to disperse the SPs. Error bars represent the standard
error evaluated on six measurements.
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the protein ﬁlm. This selective mechanism of release has been
demonstrated through both in vitro and in vivo studies
indicating the suitability of the developed SPs s for future
applications in diagnosis and therapy.
RESULTS
Supraparticle Self-Assembly. We have devised a strategy
to prepare water-dispersible and biocompatible SPs composed
of a core of hydrophobic DT-protected AuNPs (DT-AuNPs)
conﬁned by a HFBII shell (see Figures 1 and S1). In fact, we
exploited the surfactant properties of HFBII33−35 to transfer
and disperse DT-AuNPs from hydrophobic solvents into
aqueous solutions. Brieﬂy, the optimized strategy consisted of
a one-pot procedure starting from a two-phase system, HFBII@
water/DT-AuNP@chloroform, which was ﬁrst completely
dried to form a hybrid ﬁlm and subsequently rehydrated with
formation of the desired SPs (details in the methodology
section of the SI).
Interfacial surface tension measurements conﬁrmed the
ability of HFBII to decrease the energy both at the water/
chloroform and water/DT-AuNP@chloroform interfaces by
formation of a protein ﬁlm (Figure S2). Moreover, a kinetic
study showed that, during the initial two-phase step, formation
of SPs in the aqueous solution was almost immediate when the
two phases came into contact and NP concentration in the
aqueous phase increased continuously (Figure S3). These
ﬁndings suggest that SP formation is driven by an
emulsiﬁcation process, and solvent droplets containing DT-
AuNPs are stabilized at the interface by the HFBII ﬁlm.
Successive removal of the solvent did not alter the SP structure
that kept the initial arrangement upon rehydration (see
preparation methodology below).
The structural characterization of the obtained SPs is
reported in Figure 2a−g. TEM analysis showed the presence
of spherical-like nanocontainers with a mean diameter of
around 30 nm ﬁlled with an assembly of DT-AuNPs (Figure
2a,b). These dispersions were studied by a multiangle dynamic
light scattering (DLS) analysis resulting in an averaged
hydrodynamic diameter (⟨DH⟩) of 112 nm (Figure S4) and
UV−vis spectroscopy showing a characteristic localized surface
plasmon resonance (LSPR) peak centered at 520 nm (Figure
2c,d). In Figure 2e the invariance of DLS autocorrelation
functions over two months indicates the high colloidal stability
of these dispersions. Colloidal stability (Figure 2f) was also
evaluated by DLS and zeta-potential (Z-pot) analyses as a
function of the pH: The formed SPs were dispersed in diﬀerent
buﬀer solutions at the same ionic strength ranging from pH 4
to 8.
The dispersions showed a decreased colloidal stability at pH
= 5 caused by a drop of the Z-pot close to 0 with a subsequent
slight agglomeration. This behavior is due to HFBII that at its
pI (isoelectric point), at pH = 5.2, is in its zwitterionic form
with a net charge close to 0.36 Overall, these data highlight the
high colloidal stability of the prepared SPs as well as their good
compatibility with physiologic pH, which is important for
biomedical purposes.
While TEM analysis did not highlight the presence of the
protein coating due to the low contrast of the organic material,
electron energy loss spectroscopy (EELS) measurements
enabled us to evaluate the chemical composition of the hybrid
system (Figure 3a). EELS pseudocolor images (Figures 3b−d)
of the corresponding TEM pictures revealed the distribution of
nitrogen (red), carbon (green), and gold elements on the SP
surface (circled dark SPs in the N−C overlaid picture). The
good overlay of the EELS signals attributed to the N and C
elements emphasizes the protein shell around the self-
assembled DT-AuNPs. This was also conﬁrmed by FTIR
analysis that showed characteristic peaks of the protein in the
SP spectrum (Figure 3e). More information on the secondary
structure of HFBII in the layer surrounding the SPs was
obtained by circular dichroism (CD). CD spectra of the SP
dispersions highlighted that the formation of the HFBII ﬁlm
was accompanied by a change in the secondary structure of the
protein compared to pure HFBII, shown by a decrease in
intensity of the peak at 200 nm and appearance of an
absorption band at 225 nm (black curve in Figure 3f), as
expected when the protein forms a ﬁlm at a hydrophobic/
hydrophilic interface.37 Furthermore, the obtained SP dis-
persions could be lyophilized and redispersed in water
Figure 3. Structural characterization of the SP bionano interface.
(a) High-resolution TEM image obtained after drying a SP water
dispersion on a TEM holey grid. (b−d) EELS elemental mapping of
the SP surface: (b) nitrogen (N, red), (c) carbon (C, green), and
(d) overlay of the nitrogen and carbon signals (yellow). The darker
spots in (b,c) highlighted as dashed circles in (d) are AuNPs. (e)
FTIR spectra of DT-AuNPs (black line), dried HFBII from a 0.1
mg/mL water solution (blue line), and SP (red line). The spectrum
of the SP sample is a combination of the signals of DT-AuNPs and
HFBII spectra. (f) CD spectra of a water solution of HFBII (green
dots, 1 μM) and a water dispersion of SPs containing a comparable
amount of HFBII (black dots).
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maintaining their initial morphology (Figure S5), thus oﬀering
the possibility to be stored as powders rather than in solution.
Storage of biomedical formulations as powder is generally
preferred, as in this form they are better preserved and for
longer time.38
Supraparticle as Nanocontainers: Behavior in Bio-
logical Fluids. The possibility of using these SPs as potential
biomedical nanocontainers depends on their colloidal stability
and ability to encapsulate and release hydrophobic molecules in
physiological conditions as well as in biological ﬂuids. In order
to prove SP colloidal stability in biological ﬂuids, we prepared
SP dispersions in cell culture media (DMEM) containing 10%
fetal bovine serum (FBS) and in plasma obtained from healthy
mice. These dispersions were stable at DLS analysis for over 96
hours (h) at 37 °C (Figure S6). TEM analysis of the same
samples indicated that the SP structure was preserved also after
incubation in the biological milieu (Figure S6).
Having obtained a stable single nano-object that could
simultaneously bear a high amount of Au (potential diagnostic
purpose) and an extended conﬁned hydrophobic environment,
we next aimed at eﬀectively encapsulating hydrophobic cargo
molecules. Thus, we initially encapsulated the hydrophobic
ﬂuorescent dye Nile Red (NR) in the core of the SPs (SP@NR,
scheme in Figure 4a). FTIR and UV−vis analysis of SP@NR
showed the successful encapsulation of the dye (Figure S7),
while DLS indicated that the size was similar to that of the
unloaded SPs. It is known that proximity of the dye with the
AuNPs induces a ﬂuorescence quenching on NR emission,39
thus this eﬀect was used to monitor the release of the dye as
increase in ﬂuorescence (Figures 4c−h and S8). Initially, we
studied the release of NR from SP@NR through dialysis versus
a 2% (w/v) bovine serum albumin (BSA) solution over 8
days.40 The presence of BSA should guarantee a better
solubility of the NR and mimic the biological environment.
We observed a slow NR release proﬁle as shown in Figure 4c,
which could be ﬁt by a Peppas model41 and resulted in a non-
Fickian diﬀusion mechanism (super case II transport) with a
t1/2 = 194 h (details reported in Table S1). The most striking
result was that after 8 days, about 50% of dye was still retained
in the SPs. To strengthen these results and demonstrate the
eﬃciency of the developed system as carrier of hydrophobic
cargoes, a time-scan ﬂuorescence measurement of the SP@NR
Figure 4. SP ability to encapsulate and release hydrophobic cargo molecules. (a) Chemical structures of DT chains and encapsulated
ﬂuorescent molecule NR. Carbon atoms are represented in gray, nitrogen in blue, oxygen in red, and sulfur in yellow. (b) Schematic sketch of
the mechanism to detect the release of the ﬂuorescent cargo molecules from the SP in biological ﬂuids: Encapsulation of NR leads to
quenching (SP@NRQ) of its ﬂuorescence. In the presence of biological ﬂuids, the potential partition of NR from the SP (SP@NRF) to the
surrounding environment leads to a restoration of NR ﬂuorescence that can be monitored. (c) In vitro release experiments in sink conditions.
NR-loaded SPs were dialyzed versus 2% (w/V) BSA solution over time. The release proﬁle was obtained by measuring NR ﬂuorescence (λEx =
535 nm, λEm = 630 nm and ﬁt by a Peppas release model (red line). (d) Representative measurements of NR release dynamics in FBS by
ﬂuorescence experiments. The normalized (Norm) NR ﬂuorescence represents the amount of NR still associated with SPs after incubation in
10% FBS (red circles), 55% FBS (blue circles), water (black circles), or ethanol (yellow circles), respectively. Release kinetics data were ﬁt by
a two-compartment model (black and red solid lines). (e) Temperature dependence of the NR release in 10% FBS. (f) Scheme showing the
release of NR in response to SP incubation with GSH and corresponding change of the ﬂuorescence properties of the SP dispersions. (g)
Color evaluation of SP@NRQ dispersions upon incubation with GSH (SP@NRF). The cuvette was illuminated under an UV lamp (λEx = 340
nm). (h) The % increase of NR ﬂuorescence signal of a SP@NRQ dispersion incubated with GSH with respect to the control SP@NRQ
incubated in GSH free medium.
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overnight was performed in diﬀerent environments: water, 10%
FBS, and 55% FBS at both 25 and 37 °C (Figures 4d,e). While
almost no loss of NR was observed after 18 h in water, as
expected, the presence of proteins in solution promoted NR
release.6 The curves were analyzed with a two-compartment
decay model6 resulting in a remaining NR cargo of about 60%
and 35% of the initial value after 18 h in 10% and 55% FBS,
respectively (details in Table S2 and in the SI). The
temperature did not show major eﬀects on the release. These
results indicated that loaded SPs have an exceptional eﬃciency
in retaining hydrophobic cargoes in biological milieus if
compared to other nanocarriers.6,42,43 It is likely that the
HFBII impermeable and rigid ﬁlm coating the SPs is
responsible for the delayed release of the encapsulated
molecules.
Intrigued by the possibility to trigger the sudden release of
the drug cargo in vivo by disrupting the HFBII ﬁlm, we studied
the stability of the SPs in reducing environment. In fact,
because the SP bionano interface mostly formed by HFBII ﬁlm
(only a tiny protein corona formed in serum, data not shown),
the reducing intracellular environment could strongly aﬀect its
integrity. In particular, glutathione (GSH)44,45 (intracellular
concentration 5−10 mM) reduces the internal disulﬁde bridges
of HFBII, thus changing its secondary structure (Figure S9)
and most probably aﬀecting its ﬁlm-forming ability.
Empty SPs were incubated in a solution of BSA (10 mg/mL)
with increasing GSH concentrations in a range comparable to
its intracellular values and monitored by UV−vis over time.
The GSH threshold activation concentration at which SP
disassembly starts is between 0.5 and 1.0 mM, as demonstrated
by the sharp decrease of the plasmon intensity and appearance
of a precipitate in the SP aqueous dispersion. The color of these
dispersions signiﬁcantly changed (Figure S10) from purple to
light gray with formation of a dark precipitate (uncoated DT-
AuNPs). UV−vis and DLS analyses of the SP aqueous
dispersion incubated with GSH showed the disappearance of
the plasmon peak and formation of aggregates, respectively
(Figure S9). These results are explained by a progressive
dismantling of the HFBII ﬁlm with loss of stability of the SPs
and exposure of their hydrophobic content (DT-AuNPs) into
the aqueous solution, which led to aggregation and
precipitation of the so-formed AuNP aggregates (Figure S11).
This mechanism, taking place also in a biological milieu, may
Figure 5. In vitro biological behavior of the SP aqueous dispersions. (a) MTT cell viability test performed incubating diﬀerent cell lines with
increasing concentration of SPs over a time course of 24 h. Untreated cells were used as control. Experiments were carried out in DMEM with
10% FBS in triplicates. The SP concentration tested in terms of mg of Au/L were: 10.82, 5.46, 2.73, 1.08, 0.11, and 0.01 mg/L. (b) Evaluation
of SP uptake by HeLa: 450,000 HeLa cells have been challenged with 3.8 × 1010 SPs for 24 h and imaged by CLSM. Cells were stained for cell
membrane (Cell Mask) and nucleus (DAPI), while SP were imaged through their scattering properties (reﬂection). Red arrows indicate the
presence of SPs localized in a perinuclear region inside the cell. (c) Orthogonal representation of SP uptake by HeLa cells imaged as describe
in (b). The inset reports the SP uptake quantiﬁcation by ICP-AES in terms of gold content associated with the treated cells. The standard
error is calculated on three diﬀerent replicates. Scale bars are 15 μm. (d) Evaluation of Bodipy-loaded SP uptake in HeLa cells. Cells were
stained and imaged as described in (b), and Bodipy was imaged in the far-red channel. Scale bars are 20 μm. (e) Single cell confocal
microscopy and orthogonal representation of a HeLa cell treated with Bodipy-loaded SP. Scale bar is 20 μm.
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potentially occur in vivo, endowing these SPs with an intrinsic
and selective intracellular degradation pathway.
Moreover, an additional evidence was obtained incubating
SP@NR at 37 °C with 10 mg/mL of BSA in the presence of 5
mM GSH (above the threshold) along a kinetic time course.
Fluorescence emission experiments showed that samples
treated with GSH (also displaying a diﬀerent color with respect
to the untreated samples) were characterized by an increased
ﬂuorescence emission linked to an augmented release of NR.
This was also conﬁrmed with stability studies by incubating the
SPs with 3 mM GSH at 37 °C for 24 h.
Pharmacological and Pharmacokinetic Properties of
the SPs in in Vitro and in Vivo Conditions. The
biocompatibility of the empty SPs was evaluated by measuring
the possible toxicity in ﬁve diﬀerent cell lines (human cervical
adenocarcinoma HeLa, human osteosarcoma MG-63, human
glioblastoma U-87 MG, triple negative human breast
adenocarcinoma MDA-MB-231, and triple negative murine
breast adenocarcinoma 4T1) as a function of the SP
concentration. No relevant alteration of the viability was
observed in all cell lines (>80%) (Figures 5a and S12).
Confocal laser scanning microscopy (CLSM) experiments on
HeLa cells treated with the highest concentration used in the
cytotoxicity experiments revealed that SPs were internalized in
the cell cytoplasm (Figure 5b,c). In particular, the SP appeared
localized within vesicular structures accumulating in the
perinuclear region consistently with their recruitment into
endolysosomal structures (Figure 5b,c).43 SP uptake in HeLa
cells was evaluated by ICP-AES as internalized Au content and
24 h incubation resulted in 10% of the administered SP dose
taken up by the cells (inset in Figure 5c). Cellular uptake of
loaded SPs with the hydrophobic ﬂuorophore Bodipy (SP@
Bodipy, Figures S13−S14 for their characterization and release
kinetics upon incubation with GSH) was evaluated in HeLa
cells as ﬂuorescence emission of the encapsulated dye as well
(Figures S12−S13). In particular, HeLa cells incubated with
SP@Bodipy for 24 h (Figure 5d,e) showed both intracellular
internalization of the dye in the perinuclear region and a blurry
cytosolic localization. While a dotted-like perinuclear pattern is
generally consistent, as seen above, with encapsulation inside
the endosomes, a cytosolic homogeneous ﬂuorescence usually
appears when the dye is already released from the SPs.
To validate this hypothesis, we performed experiments by
administering to the cells Bodipy solutions in DMSO. In this
case, CLSM analysis reported a diﬀerent intracellular local-
ization of the free ﬂuorophore that, upon crossing the cell
membrane by passive diﬀusion, seemed to be homogeneously
localized in the cytosolic compartment (see Figure S15). To
better elucidate the release mechanism of the dye from SP@
Bodipy, we used HEK293-GFP cell lines stably expressing a
cytosolic form of the green ﬂuorescent protein (GFP, Figure
S16). These cells were incubated with SP@Bodipy for 24 h and
ﬂuorescence microscopy analysis of the sample highlighted a
partial intracellular release of the dye as appearance of yellow
areas inside the cells due to colocalization of the GFP with free
Bodipy signals. However, red-dotted areas due to the presence
of SP@Bodipy were also present in the perinuclear region,
indicating a delayed and prolonged release of the ﬂuorophore
over time.
Having demonstrated the ability of the loaded SPs to
intracellularly deliver hydrophobic cargoes, we prepared and
characterized SPs containing a prototypic hydrophobic
anticancer drug, paclitaxel (PTX) (SP@PTX) (Figure S13).
SP@PTX release kinetics in BSA solutions, also in the presence
of GSH, were measured and resembled the behavior displayed
by those containing the ﬂuorescent cargoes (Figure S13). The
possible cytotoxic eﬀects of the SP@PTX were investigated
with respect to the free drug on PTX-sensitive (Hela, MDA-
MD231) and PTX-resistant (4T1) cancer cells.46,47 Encapsu-
lation of the PTX in the SPs resulted in 1 or 2 orders of
magnitude reduction of the drug IC50 with respect to the free
drug (Figures 6a−d and S10−14). Moreover, due to the
progressive drug release from the SP core, we observed a clear
time-dependent eﬀect of the PTX only when loaded in SPs
(Figure S18).
The assessment of the interaction between tumor cells and
the developed SPs is essential for their application as diagnostic
or therapeutic tools. However, in vitro eﬃcacy is not suﬃcient
to prove the in vivo eﬀectiveness of a nanocarrier, as to exert its
pharmacological activity, the nanocarrier has to be stable in the
in vivo biological environment before reaching the pathological
target.6
In the perspective of using these SPs for biomedical
applications either as diagnostic or therapeutic tools, longi-
tudinal analyses of both in vivo biodistribution (using SP@
Bodipy) and pharmacokinetics (using SP@PTX) were
performed in healthy mice after intravenous (iv) admin-
istration. First, the fate of SP@Bodipy, both considering gold
and loaded dye, was evaluated through in vivo and ex vivo
studies (Figures 7). Figure 7a shows serial scans of the same
mouse treated with SP@Bodipy at diﬀerent time-points. Very
interestingly, a progressive increase of the signal was observed.
This is apparently in contrast with the largest part of the
experiments of optical imaging performed with ﬂuorescent
dyes, in which clearance and excretion lead to a time-dependent
Figure 6. Pharmacological proﬁle of the hydrophobic drug
molecule PTX encapsulated in the SPs. (a) Dose−response
cytotoxic eﬀect evaluated through an MTT assay on MDA cells
incubated with PTX-loaded SPs (SP@PTX) and free PTX (PTX)
after a pharmacological treatment of 48 h. Data points are the
mean, and standard errors are obtained on six experimental
replicates. (b) SP@PTX and PTX IC50 as evaluated from
experiments in (a). (c) Dose−response cytotoxic eﬀect evaluated
through an MTT assay on 4T1 cells incubated with PTX-loaded
SPs (SP@PTX) and free PTX (PTX) performed after a
pharmacological treatment of 24 h. Data points are the mean and
the standard errors obtained from six experimental replicates. (d)
SP@PTX and PTX IC50 as evaluated from experiments in (c).
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reduction of the signal. Here, considering that gold has a
quenching eﬀect on the emission of the dye (as demonstrated
in the previous in vitro experiments), the initial increase in
ﬂuorescence (24 h) is interpreted as due to the disassembling
of the SP@Bodipy supraparticles once they have reached the
organs and penetrated into the cells. Moreover, dissociation
between gold (carrier) and Bodipy (cargo) is mainly associated
with the abdominal region until 24 h after the treatment, and at
the 96 h, it spreads in diﬀerent regions, including lymph nodes
and thoracic and pelvic areas. The actual migration of the SP@
Bodipy in ﬁlter organs is demonstrated by comparing Figure
7b,c. In Figure 7b representative images of liver sections stained
with the nuclear markers Hoechst 33258 (blue) are reported.
The upper panel depicts a progressive increase of Bodipy (red
staining) in these sections until 24 h after the treatment,
followed by a decrease at the last time point. This trend is in
agreement with in vivo optical imaging and furthermore
conﬁrms the hypothesis of a disassembling of the adduct
gold-dye inside the organ. Higher magniﬁed pictures of the liver
parenchyma at 4 and 96 h after treatment, respectively, are
reported in the lower panel of Figure 7b. The presence of red
staining around the nuclei was observed at both time points,
suggesting that an active internalization inside the cells is
required to detect Bodipy ﬂuorescent signal. The main
diﬀerence is the anatomical localization of the dye; in the
liver of the mouse sacriﬁced 4 h after the treatment, it is almost
homogeneously diﬀused, whereas 96 h after the administration,
it is conﬁned in ramiﬁed and polarized cells with smaller nuclei
that very likely belong to the Kupﬀer cells. The accumulation of
gold in the Kupﬀer cells, investigated through histological
analysis by autometallography (AMG) (Figure 7c, lower panel,
right) strongly suggests that intact SP@Bodipy enters in the
cells and then disassembles, allowing the release of the dye and
consequently the detection of ﬂuorescence. Figure 7c, upper
panels, shows the kinetics of gold accumulation in liver (black
spots) in full agreement with the ﬂuorescent trend: The highest
level of the signal is after 24 h with a progressive reduction over
time. Moreover, gold accumulation was not homogeneously
spread in the whole parenchyma, but it seemed more localized
in thin and ramiﬁed cells (most probably macrophages and
Kupﬀer cells). Overall, in vitro and in vivo results obtained using
SP@Bodipy suggest that (1) the cargo is eﬃciently retained
into the carrier until its cellular internalization and (2) the
presence of a reducing environment (GSH) intracellularly
induces disassembly of the complex. Further experiments were
conducted in order to evaluate the pharmacokinetics of NP@
PTX in comparison with the classical cremophor-based
formulation of PTX in terms of release and biodistribution.
Figure 8a shows the pharmacokinetic proﬁle of PTX in
plasma of mice receiving 20 mg/kg either freely injected in
cremophor or loaded into the SPs. The levels of the drug in the
bloodstream of the animals treated with SP@PTX were
markedly lower than the other group and rapidly decreased
disappearing 4 h after administration. This diﬀerence could be
due to a rapid distribution of the SP@PTX into the main ﬁlter
organs. In fact, the levels of PTX recovered in the liver were
higher after the administration of SP@PTX than cremophor-
PTX (Figure 8d). The rapid and strong tropism to the ﬁlter
organs is furthermore demonstrated by the increase of splenic
and pulmonary levels of PTX in the group treated with SPs
(Figure S19). This result conﬁrms that the low amount of PTX
and gold in the plasma is mainly due to a rapid sequestration of
the SPs. To assess that this sequestration was actually related to
an active penetration of the SPs in the liver parenchyma, ICP-
MS measurements were carried out in the same mice, and the
trend of PTX and gold SPs was comparable at diﬀerent time-
points (Figures 8e-f). Similarly to what we found for the liver,
the curves of the kinetics of gold and drug in plasma showed a
similar proﬁle, strongly suggesting a stable association between
PTX and the gold carrier after administration in the systemic
circulation.
Even if a single administration of 20 mg/kg of PTX alone is
normally well tolerated, we could not exclude an additive eﬀect
played by gold accumulation. To evaluate histopathological
alterations, representative H&E-stained sections from spleen,
liver, and lungs of animals sacriﬁced 96 h after treatment with
PTX and SP@PTX were compared to those of untreated mice
(Figure S20). Our data did neither reveal any macroscopic
modiﬁcation of parenchyma nor features of inﬂammation and
necrosis. As in the case of SP@Bodipy, in vivo studies suggest
that SP@PTX supraparticles are stable in vivo, accumulate in
ﬁlter organs, and are able to release their cargo once penetrated
into the cells.
Figure 7. (a) In vivo biodistribution of SP@Bodipy after iv
administration in the same mouse. The ﬂuorescence signal
intensity, measured as normalized photon counts (NC), is shown
as a pseudocolor scale bar. The scale bar is consistent for all
images. (b) Liver sections from untreated and SP@Bodipy-treated
mice sacriﬁced 4, 24, 96 h, respectively. In blue, the nuclei were
stained with Hoechst 33258, and in red, the signal is associated
with Bodipy. (C) Liver sections from untreated and SP@Bodipy-
treated mice sacriﬁced 4, 24, 96 h, respectively. Black spots are
representative of the gold accumulation revealed by silver lactate,
and the parenchyma was revealed by Safranin O staining.
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DISCUSSION
We have developed a facile and eﬃcient methodology, which
exploits HFBII surfactant and ﬁlm-forming properties, to
assemble hydrophobic AuNPs into water-stable and biocom-
patible SPs stable in the biological environment. These water-
dispersible SPs possess an extended inner hydrophobic
compartment that can be exploited for drug loading. This
highly hydrophobic core matches the physicochemical proper-
ties (such as hydrophobicity and solvent miscibility) of most
conventional chemotherapeutics and is able to avoid the release
of hydrophobic drugs in the systemic circulation before
reaching tissue parenchyma.6,48 In fact, the importance of the
cargo-carrier compatibility for reducing undesired release of
poorly soluble drugs has been recently demonstrated for
polymeric PLGA (poly(lactic-co-glycolic acid) NPs in vivo.6,42
Similarly, our release experiments on the developed SPs
demonstrated a high ability to retain the cargoes inside the
carrier in biological ﬂuids, which represents one of the main
hurdles on the targeted delivery of nanodrugs. On the other
hand, a sudden release of the drug upon SP uptake by the cells
is triggered by the reducing action of the intracellular GSH,
which promotes breakage of the HFBII coating. As a
consequence, an encapsulated anticancer drug, SP@PTX,
showed 2 orders of magnitude decrease of its IC50 in in vitro
experiments on target cells. Through an elegant and original
approach combining in vivo tracking of the SPs with either a
ﬂuorescent dye or a drug, we were able to demonstrate the
working hypotheses postulated above. In particular, this study
highlights the reliability of the developed system for its
intracellular delivery with minimal dispersion of the payload.
Although other steps, such as the functionalization of the
surface to pass through biological barriers and/or to reach
speciﬁc targets will have to be considered, we believe that the
demonstration of this general behavior may represent a robust
starting point to think about a next generation of nanocarriers.
The obtained SP represents a theranostic nanosystem able to
simultaneously carry high content of AuNPs and drugs,30 but
also, by means of the impermeable HFBII coating, prevents
leakage of the drug.31,32 AuNPs were chosen for their easy
preparation49 and bioinertness,49,50 along with the possibility to
use the high content of Au in the SP core as diagnostic and
therapeutic tool (in fact, gold provides nearly 3-fold greater X-
ray attenuation per unit weight than iodine) in computed
tomography and radiation therapy10,51,52 applications. The
applicability of the developed methodology is general and may
be applied to the obtainment of a broad variety of new SPs, for
example, ﬂuorinated ones. Furthermore, the possibility to
modify chemically or genetically, that is, fusion proteins,53 the
HFBII shell allows for further functionalization of the SP
surface for targeting speciﬁc tissues. Overall, these results are
important for guiding advances in the design of multistage and
multimodal nanosystems for diagnosis and therapy.
METHODS
Procedure to Prepare the HFBII-Stabilized SPs. 900 μL of DT-
AuNP (stock concentration about 1−3 × 1015 NPs/mL) were
precipitated using ethanol (≅10 mL) and centrifuged at 8000 rpm for
30 min. The obtained pellet was dried using compressed air,
resuspended in 900 μL of chloroform and moved in a round
bottomed ﬂask. HFBII was obtained as described in reference.54 A
fresh solution of HFBII 0.1 mg/mL was prepared by dissolving an
accurately weighed amount of the protein in Milli-Q water (mQw)
under sonication for 15 min using a bath. NP dispersion was then
placed in a water bath at 50 °C and stirred magnetically (>300 rpm).
The freshly prepared HFBII solution was added dropwise to the NP
dispersion and subsequently the NP/HFB biphasic solution was left
under magnetic stirring at 50 °C for 1 h. During stirring CHCl3 and
aqueous phases were vigorously mixed and the aqueous phase
gradually turned pink, as a consequence of NP transfer into the
aqueous phase via SPs formation. The sample was subsequently dried
Figure 8. Levels of PTX in (a) plasma and (d) liver measured by HPLC after iv treatment with free PTX or SP@PTX in healthy mice. Levels of
gold in (b) plasma and (e) liver measured by ICP-MS after SP@PTX injection. Each group has three mice as replicates. Data are expressed as
mean ± SE. Two way-ANOVA followed by Bonferroni posthoc test was carried out. Multiple comparisons (matching both treatments and
time points) show a signiﬁcant diﬀerence in kinetics and biodistribution of the two formulations. Trend of levels of both gold and PTX in (c)
plasma and (f) liver derived from mice treated with SP@PTX. The values were normalized to 1 at the ﬁrst time point (10 min).
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using rotavapor. Evaporation was gradually performed at room
temperature leading to the formation of a dried ﬁlm. The dried ﬁlm
was dissolved in mQw (10 mL) and subject of ultrasound bath for 15
min. The obtained SP dispersion was left overnight at RT and dialyzed
against mQw for 24 h.
Three 1 min-tip-sonication cycles were performed on the dialyzed
sample using a SONIC Vibracell (Newtown, CT) operating at 20 V
and set at 80% power. For dye and drug encapsulation, the molecule to
be encapsulated was dissolved in 200 μL of the organic phase (CHCl3)
and incubated overnight with 800 μL of the NP dispersion. After that
the encapsulation of the drug and the NPs to form SPs was
accomplished following the same procedure explained above to
prepare empty SPs. The puriﬁcation of the drug loaded SPs was
performed by centrifugation: ﬁrst centrifugation run (speed 1000 g for
20 min); second centrifugation run (5000 g for 40 min); third
centrifugation run (5000 g for 40 min). At each puriﬁcation step the
obtained supernatant was collected and analyzed by FTIR and UV−vis
to disclose the presence of free HFBII or drug molecule, while the
pellet was suspended in Milli-Q water and processed again. In a typical
puriﬁcation process three runs are suﬃcient to remove the excess free
drug in solution. SP number was evaluated as it follows: the volume of
a SP with a radius 15 nm is VSP = πr43
3 while the weight of a SP is
obtained approximately multiplying its volume to the density of gold
(19 g/cm3). The SP concentration was then obtained by dividing the
gold content of the SP preparation as measured by ICP-AES to the
approximate weight of a SP.
In vitro drug release characterization. To measure the release
pattern of Nile Red from the SP@NR, 2.5 mL of SP@NR were placed
into a dialysis bag (MWCO: 3000 Da), which was subsequently
immersed in 25 mL of aqueous media containing 2% (w/v) BSA at 25
°C under gently stirring. At predetermined time intervals, 1 mL of the
equilibrated solution was recovered and the NR content was
determined by ﬂuorescence measurement using an excitation of 535
nm and measuring the emission at 630 nm. The excitation and
emission width were ﬁxed at 5 nm while the sensitivity of the
Fluorimeter (Jasco) was set on high. In order to maintain the sink
conditions, each mL of solution recovered was replenished with a fresh
one. To evaluate the amount of NR release a calibration curve was
used. The drug release data obtained were ﬁtted to a Peppas model
using SigmaPlot.
In vivo experiments. Mice were maintained under speciﬁc
pathogen-free condition in the Institute’s Animal Care Facility and
regularly checked by a certiﬁed veterinarian. Food and water were
available for ad libitum consumption. Artiﬁcial light was provided in a
12h/12h cycle. Procedures involving animals and their care were
conducted in conformity with institutional guidelines in compliance
with national (Legislative Decree n. 26, March 4, 2014; Authorization
n.19/2008-A issued March 6, 2008, by the Italian Ministry of Health)
and international laws and policies (EEC Council Directive 2010/63,
August 6, 2013; Standards for the Care and Use of Laboratory
Animals, U.S. National Research Council, Statement of Compliance
A5023−01, October 28, 2008).
Four-week-old female BALB/c mice (CDI envigo) were enrolled
for biodistribution and pharmacokinetics study. Regarding biodis-
tribution, four animals were intravenously treated with 200 μL of SP@
Bodipy (1 × 1012 SPs/mL). Optical imaging was conducted on
animals before and at 4, 24, and 96 h after SPs injection using the
Explore Optix System (ART, Advanced Research Technologies,
Montreal, Canada), as already described by our group.55 Selected
region of interest (ROI) scan (ventral area) was performed with a step
size of 2 mm. After in vivo imaging, mice were sacriﬁced by
decapitation, and the liver was collected and immediately frozen for
histological analysis to visualize both Bodipy and gold accumulation.
As regards pharmacokinetics, animals were treated with 20 mg/kg
of cremophor PTX (n = 15) or SP@PTX (n = 15). Blood was
collected, in heparinized tubes, 10 min, 1, 4, 8, and 24 h after
treatment and centrifuged to obtain plasma. After mice sacriﬁce, liver,
spleen, and lungs were collected and stored at −20 °C until ICP-MS
analysis (to detect the presence of gold) and HPLC-UV (to measure
the levels of PTX). Elemental analysis of organs was carried out by
ICP-MS as described before (methods in the SI) to evaluate the Au
content. To measure its concentration, each organ was weighed before
the analysis. The total concentration of PTX in the diﬀerent biological
matrices was determined by HPLC as previously described.56 For the
determination of PTX in tissues and organs, they were previously
homogenized in 0.2 M CH3COONH4 pH 4.5.
Each study sample (0.3 mL for plasma and 0.5 mL for homogenate
tissues) was assayed together with a ﬁve points of standard calibration
curve prepared in the corresponding control biological matrix obtained
from untreated mice at concentrations ranging from 0.05 to 5 μg/
sample. The limits of quantiﬁcation (LOQ) were 0.16 μg/mL and 0.6
μg/g for plasma and organs, respectively
Histological Studies. Histological analyses were performed on
sections derived from mice treated with SP@Bodipy. Fluorescent
analysis was performed incubating liver cryostatic sections (30 μm of
thickness) with the vital nuclear dye Hoechst 33258 (2 μg/mL in
PBS) and then acquired by Olympus Fluoview microscope BX61
(Tokyo, Japan) with confocal system FV500 equipped by speciﬁc
lasers λexc = 405 nm for Hoechst 33258 and λexc = 635 nm to visualize
the speciﬁc signal associated with Bodipy.
Liver micrometric sections (4 μm) were cut to analyze the metal
tissue distribution, and autometallography staining was carried out by
as recently described. At the end of the staining, sections were
visualized through a light microscope for the identiﬁcation and
localization of gold aggregates, visible as black granular pigments.57
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